J 2010

Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy

BELADA, David, L. SMOLEJ, P. STEPANKOVA, P. KRALICKOVA, Tomáš FREIBERGER et. al.

Basic information

Original name

Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy

Authors

BELADA, David (203 Czech Republic), L. SMOLEJ (203 Czech Republic), P. STEPANKOVA (203 Czech Republic), P. KRALICKOVA (203 Czech Republic) and Tomáš FREIBERGER (203 Czech Republic, guarantor, belonging to the institution)

Edition

LEUKEMIA RESEARCH, Belada D Smolej, 2010, 0145-2126

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.555

RIV identification code

RIV/00216224:14110/10:00046815

Organization unit

Faculty of Medicine

UT WoS

000280576500029

Keywords in English

HYPERIMMUNOGLOBULINEMIA-E; HODGKIN LYMPHOMA; JOBS-SYNDROME; MUTATIONS
Změněno: 16/1/2011 00:35, prof. MUDr. Tomáš Freiberger, Ph.D.

Abstract

V originále

A case of patient with hyper-IgE syndrome and diffuse large B-cell lymphoma who achieved a durable remission after modified immunochemotherapy is rported. Heterozygous point mutation (c.1259A > C) in codon 340 of the DNA-binding domain of STAT3 was detected in the patient .